$47.100
-0.160 (-0.34%)Al cierre
Predicciones de precio
Ábrelo en la app para desbloquear previsiones a más largo plazo.
Predicción y previsión de LBRX por análisis de gráficos similares
Alphio's LBRX stock price prediction model matches the current LB Pharmaceuticals Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $46.95 (-0.32%). The 1-week path is $43.66 (-7.30%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
¿Debería comprar acciones de LB Pharmaceuticals Inc?
LB Pharmaceuticals Inc is a good buy right now due to its current price of $47.73, which is below the analyst price targets of $60 and $69, suggesting significant upside potential. The stock has shown a remarkable year-to-date change of +133.51% and a one-year change of +218.20%, indicating strong momentum. However, the main risk is the negative earnings per share (EPS) of -1.71 reported in the last earnings, which reflects ongoing financial challenges that investors should monitor closely.
LBRX cerró en $47.10 el Tuesday, tras bajar -0.34%
LB Pharmaceuticals Inc (LBRX) last closed at $47.1, losing -0.34%. These facts feed the 1-day and 1-week LBRX price prediction above.
Factores de la previsión
Los factores de la previsión de LB Pharmaceuticals Inc (LBRX) combinan patrones gráficos similares, estacionalidad y medias móviles.
Similar patterns
Bullish
Seasonality
Bullish
SMA 20
Bearish
SMA 200
Bullish
Patrones gráficos similares
Acciones cuya trayectoria reciente más se parece a la de LBRX, ordenadas por similitud.
Análisis de estacionalidad de LBRX
Historically the probability of a positive September return for LBRX is 75.00%. February offers the highest probability of a positive month at 100.00%, while January is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.